Skip to main content
Caplight Logo









Oculogica

Oculogica

Private
New York City, New YorkHealthcare & Life Scienceshttps://oculogica.com/

Last Round

Series B

May 13, 2024

Est. Valuation

$51.62M

Total Funding Raised

$23.35M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Oculogica is a neuro-diagnostic company that develops and commercializes eye-tracking medical devices for the objective assessment of concussions and other brain injuries.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts, Services & Consulting

AI Layer

Application

Keywords

concussion diagnosiseye-tracking technologytraumatic brain injuryTBImedical diagnostic deviceconcussion testdigital biomarkermedical AIsports medicinecranial nerve functionsideline testingneurology diagnosticcurrent procedural terminologyCPT codeshealth tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oculogica Comparables

Compare Oculogica with similar companies based on industry and business-model similarity.

Oculogica comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BrainScope
88%
NeuroSync
85%
RightEye
83%

Oculogica Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 13, 2024
GrantMay 18, 2021
Series AJan 16, 2020
GrantJun 1, 2018
SeedJul 16, 2014
Angel
May 20, 2014

Key People

Founding team and executive leadership

Joel Sanderson

Chief Technology Officer

Executive Team

Oculogica Investors

Notable investors and investment history

Oculogica investors
InvestorRounds
NIH RADxGrant
Sofia FundSeries A
U.S. Army Medical Research and Development CommandGrant
TitletownTechSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 37% MoM, from 2.2K to 3K.

  • May 19, 2026

    Monthly visitors increased 42% MoM.

Oculogica Filings

Explore SEC and related filing metadata, where available.

Oculogica filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Oculogica's valuation, stock price, and market status.

Is Oculogica a public or private company?

Oculogica is a private company.

What is the current stock price of Oculogica?

Oculogica is a private company with no public stock price. No recent secondary market data is available.

How much is Oculogica worth (valuation)?

Oculogica's valuation is estimated at $51.6M based on funding round data.

Can I buy Oculogica stock?

Oculogica shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Oculogica's last funding round?

Oculogica's most recent funding round was Series B on May 13, 2024.

Who are the main investors in Oculogica?

Key investors in Oculogica include TitletownTech.

Will Oculogica IPO soon?

No public IPO plans have been announced for Oculogica.

How can I track Oculogica secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Oculogica's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Employee Range12
Year Founded2013
Last FundingMay 13, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?